Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 7/2014

01-07-2014 | Substantive Review

Impact of Geographic and Transportation-Related Barriers on HIV Outcomes in Sub-Saharan Africa: A Systematic Review

Authors: Alexander J. Lankowski, Mark J. Siedner, David R. Bangsberg, Alexander C. Tsai

Published in: AIDS and Behavior | Issue 7/2014

Login to get access

Abstract

Difficulty obtaining reliable transportation to clinic is frequently cited as a barrier to HIV care in sub-Saharan Africa (SSA). Numerous studies have sought to characterize the impact of geographic and transportation-related barriers on HIV outcomes in SSA, but to date there has been no systematic attempt to summarize these findings. In this systematic review, we summarized this body of literature. We searched for studies conducted in SSA examining the following outcomes in the HIV care continuum: (1) voluntary counseling and testing, (2) pre-antiretroviral therapy (ART) linkage to care, (3) loss to follow-up and mortality, and (4) ART adherence and/or viral suppression. We identified 34 studies containing 52 unique estimates of association between a geographic or transportation-related barrier and an HIV outcome. There was an inverse effect in 23 estimates (44 %), a null association in 26 (50 %), and a paradoxical beneficial impact in 3 (6 %). We conclude that geographic and transportation-related barriers are associated with poor outcomes across the continuum of HIV care.
Appendix
Available only for authorised users
Literature
1.
2.
Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509–15.PubMedCrossRef
3.
Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257–65.PubMedCentralPubMedCrossRef
4.
Maman D, Pujades-Rodriguez M, Nicholas S, et al. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/ml. AIDS. 2012;26(11):1393–8.PubMedCrossRef
5.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.PubMedCrossRef
6.
7.
Geng EH, Hare CB, Kahn JO, et al. The effect of a “universal antiretroviral therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/mL in a public health setting. Clin Infect Dis. 2012;55(12):1690–7.PubMedCentralPubMedCrossRef
8.
World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access; 2011.
9.
Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.PubMedCrossRef
10.
Brinkhof MW, Spycher BD, Yiannoutsos C, et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS ONE. 2010;5(11):e14149.PubMedCentralPubMedCrossRef
11.
Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS ONE. 2011;6(12):e28691.PubMedCentralPubMedCrossRef
12.
Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.PubMedCrossRef
13.
Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retrovir. 2008;24(4):555–60.PubMedCrossRef
14.
Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.PubMedCentralPubMedCrossRef
15.
16.
Losina E, Bassett IV, Giddy J, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS ONE. 2010;5(3):e9538.PubMedCentralPubMedCrossRef
17.
Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should. AIDS. 2010;24(Suppl 1):S37–44.PubMedCentralPubMedCrossRef
18.
19.
Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7(4):234–44.PubMedCentralPubMedCrossRef
20.
Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–71.PubMedCrossRef
21.
Eisenberg JM, Power EJ. Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality. JAMA. 2000;284(16):2100–7.PubMedCrossRef
22.
Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.PubMedCentralPubMedCrossRef
23.
Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: a qualitative study. SAHARA J. 2009;6(4):148–54.PubMedCrossRef
24.
Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.PubMedCrossRef
25.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedCentralPubMedCrossRef
26.
Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059–67.PubMedCrossRef
27.
Hutchinson PL, Mahlalela X. Utilization of voluntary counseling and testing services in the Eastern Cape, South Africa. AIDS Care. 2006;18(5):446–55.PubMedCrossRef
28.
Kaawa-Mafigiri D, Mcgrath J, Namutiibwa F, et al. Delays in seeking HIV/AIDS testing and treatment among patients on ARVs in urban (Kampala) and rural southwestern Uganda. XIX International AIDS Conference. Washington, DC, 2012.
29.
Morin SF, Khumalo-Sakutukwa G, Charlebois ED, et al. Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. J Acquir Immune Defic Syndr. 2006;41(2):218–24.PubMedCrossRef
30.
Minstry of Health Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey 2004–2005. Calverton: Ministry of Health and ORC Macro; 2006.
31.
Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.PubMedCentralPubMedCrossRef
32.
Parkes-Ratanshi R, Bufumbo L, Nyanzi-Wakholi B, et al. Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health. 2010;15(11):1347–56.PubMedCrossRef
33.
Braitstein P, Songok J, Vreeman RC, et al. “Wamepotea” (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57(3):e40–6.PubMedCentralPubMedCrossRef
34.
Krebs DW, Chi BH, Mulenga Y, et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care. 2008;20(3):311–7.PubMedCrossRef
35.
McGuire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health. 2010;15(Suppl 1):55–62.PubMedCrossRef
36.
Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681–8.PubMedCentralPubMedCrossRef
37.
Adeyemo A, Tamen F, Ayebe T, Oyigebe G. Socio-gender factors as explanation for poor drug adherence among antiretroviral users. 4th International Conference on HIV Treatment Adherence. Miami; 2009.
38.
Asiimwe B, Tarinyeba E, Kyomuhendo J. Adherence results for 84 patients on anti-retroviral therapy for 1 year at Bushenyi Medical Centre, Katungu in rural south western Uganda. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.
39.
Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care. 2009;21(3):271–9.PubMedCrossRef
40.
Eholie SP, Tanon KA, Folquet-Amorissani M, et al. Impact of access to antiretroviral therapy in Cote d’Ivoire. Med Trop (Mars). 2009;69(5):520–4.PubMed
41.
Kip E, Ehlers VJ, van der Wal DM. Patients’ adherence to anti-retroviral therapy in Botswana. J Nurs Scholarsh. 2009;41(2):149–57.PubMedCrossRef
42.
Kirsten I, Sewangi J, Kunz A, et al. Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS ONE. 2011;6(6):e21020.PubMedCentralPubMedCrossRef
43.
Munseri PJ, Talbot EA, Mtei L, von Reyn CF. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037–41.PubMed
44.
Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AE, Osagbemi GK. Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. J Infect Dev Ctries. 2008;2(5):369–72.PubMed
45.
Potchoo Y, Tchamdja K, Balogou A, Pitche VP, Guissou IP, Kassang EK. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association “Espoir Vie Togo” in Togo, West Africa. BMC Clin Pharmacol. 2010;10:11.PubMedCentralPubMedCrossRef
46.
van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, Moss WJ. Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. BMC Infect Dis. 2009;9:169.PubMedCentralPubMedCrossRef
47.
Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):281–8.PubMedCrossRef
48.
Yahaya H, Gwarzo U, Liman MS. Forecasting long-term adherence to HAART in GHAIN-supported facility using client’s socioeconomic status. 1st International Conference on HIV Treatment Adherence. Miami; 2006.
49.
Assefa Y, Van Damme W, Mariam DH, Kloos H. Toward universal access to HIV counseling and testing and antiretroviral treatment in Ethiopia: looking beyond HIV testing and ART initiation. AIDS Patient Care STDS. 2010;24(8):521–5.PubMedCrossRef
50.
Bowie C, Gondwe N. Changing clinical needs of people living with AIDS and receiving home based care in Malawi: the Bangwe Home Based Care Project 2003–2008—a descriptive study. BMC Public Health. 2010;10:370–1.PubMedCentralPubMedCrossRef
51.
Chan AK, van Lettow M, Tenthani L, et al. Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study. PLoS One. 2011;6(5):e19789.PubMedCentralPubMedCrossRef
52.
Lubega M, Nsabagasani X, Tumwesigye NM, et al. Policy and practice, lost in transition: reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda. Health Policy. 2010;95(2–3):153–8.PubMedCrossRef
53.
Bwirire LD, Fitzgerald M, Zachariah R, et al. Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg. 2008;102(12):1195–200.PubMedCrossRef
54.
Abrahams N, Jewkes R. Barriers to post exposure prophylaxis (PEP) completion after rape: a South African qualitative study. Cult Health Sex. 2010;12(5):471–84.PubMedCrossRef
55.
Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(Suppl 1):82–91.PubMedCrossRef
56.
Nam SL, Fielding K, Avalos A, Dickinson D, Gaolathe T, Geissler PW. The relationship of acceptance or denial of HIV-status to antiretroviral adherence among adult HIV patients in urban Botswana. Soc Sci Med. 2008;67(2):301–10.PubMedCrossRef
57.
Nassali M, Nakanjako D, Kyabayinze D, Beyeza J, Okoth A, Mutyaba T. Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program. AIDS Care. 2009;21(9):1124–31.PubMedCrossRef
58.
Peterson K, Laly R. Patterns in the use of adherence supports. 1st International Conference on HIV Treatment Adherence. Miami; 2006.
59.
Pyne-Mercier LD, John-Stewart GC, Richardson BA, et al. The consequences of post-election violence on antiretroviral HIV therapy in Kenya. Aids Care. 2011;23(5):562–8.PubMedCentralPubMedCrossRef
60.
Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9(3):263–9.PubMed
61.
Thobias A, Van Wyk B. Issues in adherence to antiretroviral treatment in an urban setting in Namibia. 4th International Conference on HIV Treatment Adherence. Miami; 2009.
62.
Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e11.PubMedCrossRef
63.
Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One. 2010;5(4):e10340.PubMedCentralPubMedCrossRef
64.
Wringe A, Isingo R, Urassa M, et al. Uptake of HIV voluntary counselling and testing services in rural Tanzania: implications for effective HIV prevention and equitable access to treatment. Trop Med Int Health. 2008;13(3):319–27.PubMedCrossRef
65.
Cook RE, Ciampa PJ, Sidat M, et al. Predictors of successful early infant diagnosis of HIV in a rural district hospital in Zambezia, Mozambique. J Acquir Immune Defic Syndr. 2011;56(4):e104–9.PubMedCentralPubMedCrossRef
66.
Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24(17):2717–25.PubMedCentralPubMedCrossRef
67.
Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56(3):e79–86.PubMedCentralPubMedCrossRef
68.
Sutcliffe CG, van Dijk JH, Bolton-Moore C, Cotham M, Tambatamba B, Moss WJ. Differences in presentation, treatment initiation, and response among children infected with human immunodeficiency virus in urban and rural Zambia. Pediatr Infect Dis J. 2010;29(9):849–54.PubMedCrossRef
69.
Elbireer S, Guwatudde D, Mudiope P, Nabbuye-Sekandi J, Manabe YC. Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda. Trop Med Int Health. 2011;16(8):981–7.PubMedCrossRef
70.
Geng EH, Glidden DV, Bwana MB, et al. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One. 2011;6(7):e21797.PubMedCentralPubMedCrossRef
71.
Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12(5):687–94.PubMedCrossRef
72.
Kempf MC, Allen S, Zulu I, et al. Enrollment and retention of HIV discordant couples in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008;47(1):116–25.PubMedCrossRef
73.
Massaquoi M, Zachariah R, Manzi M, et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg. 2009;103(6):594–600.PubMedCrossRef
74.
Mossdorf E, Stoeckle M, Mwaigomole EG, et al. Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis. 2011;11:98.PubMedCentralPubMedCrossRef
75.
Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE. 2010;5(10):e13268.PubMedCentralPubMedCrossRef
76.
Adeyemi A, Olubunmi F, Oluseyi A. Predictors of adherence for patients on highly active antiretroviral therapy in HIV treatment program. 12th Annual International Meeting of the Institute of Human Virology. Tropea; 2010.
77.
Bagenda A, Barlow-Mosha L, Bagenda D, Sakwa R, Fowler MG, Musoke PM. Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda. Ann Trop Paediatr. 2011;31(3):235–45.PubMedCrossRef
78.
Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J. 2011;30(1):52–6.PubMedCrossRef
79.
Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV plus Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16(1):38–41.PubMedCrossRef
80.
Carlucci JG, Kamanga A, Sheneberger R, et al. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr. 2008;47(5):615–22.PubMedCentralPubMedCrossRef
81.
Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS ONE. 2010;5(5):e10584.PubMedCentralPubMedCrossRef
82.
Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS ONE. 2012;7(5):e36737.PubMedCentralPubMedCrossRef
83.
Hirschhorn L, Singal R, Navario P, Mokhele I, Patel A, Maartens G. Adherence to ART in two innovative treatment models in South Africa. 4th International Conference on HIV Treatment Adherence. Miami; 2009.
84.
Iroha E, Esezobor CI, Ezeaka C, Temiye EO, Akinsulie A. Adherence to antiretroviral therapy among HIV-infected children attending a donor-funded clinic at a tertiary hospital in Nigeria. AJAR-Afr J Aids Res. 2010;9(1):25–30.CrossRef
85.
Kurlander C, Eng ML, Charurat M, Farley JJ, Blattner WA. Evaluation of pharmacy refill rates and self-reported adherence for antiretroviral therapy at a PEPFAR clinic in northern Nigeria. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.
86.
Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. AJAR-Afr J Aids Res. 2010;9(2):117–24.CrossRef
87.
Mbaezue N, Farley J, Charurat M, Blattner WA. A case control study of nonadherence among Nigerian patients initiating antiretroviral (ARV) therapy. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.
88.
Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.PubMedCrossRef
89.
Sethi A, Bajunirwe F, Mafigiri D, et al. Distance as a barrier to adherence to antiretroviral therapy among HIV-infected patients in rural southwestern Uganda. 4th International Conference on HIV Treatment Adherence. Miami; 2009.
90.
Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2010;54(1):85–92.PubMedCrossRef
91.
van Dijk JH, Sutcliffe CG, Munsanje B, et al. HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS One. 2011;6(4):e19006.PubMedCentralPubMedCrossRef
92.
Bateman J, Garrod GD, Brainard JS, Lovett AS. Measurement issues in the travel cost method: a geographical information systems approach. J Agric Econ. 1996;47(2):191–205.CrossRef
93.
Siedner MJ, Lankowski A, Tsai AC, et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS. 2013;27(9):1503–8.PubMedCentralPubMedCrossRef
94.
95.
Turan JM, Bukusi EA, Onono M, Holzemer WL, Miller S, Cohen CR. HIV/AIDS stigma and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS Study. AIDS Behav. 2011;15(6):1111–20.PubMedCentralPubMedCrossRef
96.
Tsai AC, Bangsberg DR, Kegeles SM, et al. Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med. 2013;46(3):285–94.PubMedCrossRef
97.
Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDS. 2007;21(Suppl 1):S40–8.PubMed
98.
Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640.PubMedCentralPubMed
99.
Mekonnen Y, Sanders R, Tibebu S, Emmart P. Equity and access to ART in Ethiopia. Washington, DC: Futures Group, Health Policy Initiative; 2010.
100.
Mahler HR, Kileo B, Curran K, et al. Voluntary medical male circumcision: matching demand and supply with quality and efficiency in a high-volume campaign in Iringa Region, Tanzania. PLoS Med. 2011;8(11):e1001131.PubMedCentralPubMedCrossRef
101.
Gilbert L, Walker L. ‘My biggest fear was that people would reject me once they knew my status…’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa. Health Soc Care Community. 2010;18(2):139–46.PubMedCrossRef
102.
103.
Boyer S, Eboko F, Camara M, et al. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 2010;24(Suppl 1):S5–15.PubMedCrossRef
104.
Bemelmans M, van den Akker T, Ford N, et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health. 2010;15(12):1413–20.PubMedCrossRef
105.
Pfeiffer J, Montoya P, Baptista AJ, et al. Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique: a case study. J Int AIDS Soc. 2010;13:3.PubMedCentralPubMedCrossRef
106.
Tsai AC, Chopra M, Pronyk PM, Martinson NA. Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care. 2009;21(1):59–63.PubMedCrossRef
107.
Siedner MJ, Lankowski A, Haberer JE, et al. Rethinking the “pre” in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS ONE. 2012;7(6):e39894.PubMedCentralPubMedCrossRef
108.
109.
Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572–9.PubMedCrossRef
110.
Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav. 2011;15(4):751–60.PubMedCentralPubMedCrossRef
111.
Siedner MJ, Haberer JE, Bwana MB, Ware NC, Bangsberg DR. High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak. 2012;12:56.PubMedCentralPubMedCrossRef
112.
Emenyonu N, Thirumurthy H, Muyindike W, et al. Cash transfers to cover clinic transportation costs improve adherence and retention in care in a HIV treatment program in Rural Uganda. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco; 2010.
113.
Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S123–6.PubMedCrossRef
114.
Haberer JE, Kiwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2166–8.PubMedCrossRef
115.
Bachman Desilva M, Gifford AL, Keyi X, et al. Feasibility and acceptability of a real-time adherence device among HIV-positive IDU patients in China. AIDS Res Treat. 2013;2013:957862.PubMedCentralPubMed
116.
Haberer JE, Robbins GK, Ybarra M, et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav. 2012;16(2):375–82.PubMedCentralPubMedCrossRef
117.
Metadata
Title
Impact of Geographic and Transportation-Related Barriers on HIV Outcomes in Sub-Saharan Africa: A Systematic Review
Authors
Alexander J. Lankowski
Mark J. Siedner
David R. Bangsberg
Alexander C. Tsai
Publication date
01-07-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0729-8

Other articles of this Issue 7/2014

AIDS and Behavior 7/2014 Go to the issue

Original Paper

Critical Consciousness, Racial and Gender Discrimination, and HIV Disease Markers in African American Women with HIV

Original Paper

Provider–Patient Communication About Adherence to Anti-retroviral Regimens Differs by Patient Race and Ethnicity

Original Paper

Opioid Analgesic Misuse is Associated with Incomplete Antiretroviral Adherence in a Cohort of HIV-Infected Indigent Adults in San Francisco

Original Paper

Drinking Motives Among HIV Primary Care Patients

Original Paper

HIV Prevalence, Substance Use, and Sexual Risk Behaviors Among Transgender Women Recruited Through Outreach

Brief Report

Whoonga and the Abuse and Diversion of Antiretrovirals in Soweto, South Africa
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits